Adlai Nortye Group Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
9.55
-0.73 (-7.10%)
At close: Oct 30, 2026, 4:00 PM EDT
9.81
+0.26 (2.72%)
After-hours: Oct 30, 2026, 7:31 PM EDT
Adlai Nortye Group Earnings Call Transcripts
Fiscal Year 2026
-
The event highlighted progress on two lead oncology assets: AN9025, a potent oral pan-RAS(ON) inhibitor in phase I trials with both daily and weekly dosing, and AN4035, a first-in-class ADC targeting CEACAM5. Key clinical data are expected in 2027, supported by a strong cash position.
-
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.